Algistat® Complex

The demand for alternatives to traditional pharmacological therapies for pain treatment has greatly driven research into the origin of painful sensations. Regarding the mechanisms of pain perception, the fundamental role of cannabinoid receptors has emerged in recent years. The discovery of specific receptors for cannabinoids (CB1 and CB2) and their endogenous ligands has led to a better understanding of the pharmacological actions of cannabinoids as therapeutic agents in various pain conditions. CB1 receptors are widely distributed in the central and peripheral nervous systems, and their activation produces psychotropic effects. CB2 receptors, on the other hand, are mainly expressed by immune cells, act in the periphery, and do not show psychotropic effects. When activated, CB2 receptors can influence the release of chemical messengers, such as cytokines by immune cells. Activation of CB2 receptors induces analgesia, both through direct mechanisms involving primary sensory neurons and through indirect mechanisms mediated by immune cell receptors or other systems, such as the endogenous opioid system. Beta-caryophyllene is a natural ligand for CB2 receptors.

All the components contained in Algistat® complex, namely eugenol and beta-caryophyllene, which characterize Clove Essential Oil (Syzygium aromaticum), and DHA have a synergistic antioxidant effect and promote the well-being of the nervous system.

Il DHA (22:6 n-3 or Docosahexaenoic Acid) is a polyunsaturated fatty acid belonging to the omega-3 class. It is naturally found in plant foods, such as algae, and in numerous marine animal species. It is essential for the proper development and functioning of the nervous system. In fact, it is an important component of neuronal membranes, regulating their fluidity, permeability, and viscosity. It plays a key role in modulating neurotransmission and synaptic plasticity, and enzymatically converts into autacoids that counteract the inflammatory process. Due to these reasons, DHA deficiencies are often associated with neurological and inflammatory disorders. Once passed through the intestinal mucosa, DHA is converted into bioactive metabolites with strong antioxidant and anti-inflammatory properties that inhibit cellular pro-inflammatory metabolic pathways (such as NF-kB) and promote the synthesis of lipoxins, neuroprotectin-D, and resolvins, which are important for the complete resolution of the inflammatory process.

Algistat® complex can be used together with medications and other supplements. However, the use of Algistat® complex is not recommended in conditions of liver or kidney insufficiency, in individuals with coagulation-related disorders, or in conjunction with anticoagulant therapies. It is also not recommended for individuals with fish allergies.

Algistat® complex does not naturally contain lactose, but it is not certified lactose-free.

Algistat® complex does not naturally contain gluten, but the production process is not certified gluten-free.

Algistat® complex does not contain sugars.

The DHA contained in Algistat® complex is of animal origin, so the product cannot be considered vegan.